Inversago Pharma Completes Phase 1 Clinical Trial on First-in-Class, Peripheral CB1 Blocker and...
GPCR News
Professor Charlotte Deane Joins Exscientia as Chief Scientist of Biologics AI
Drug Discovery Picks Up the Pace, Stays on Target
Learn more about Neurocrine Biosciences with their new video
Dr. Nicola J. Smith - Dr. GPCR Podcast
Targeted Therapies to Reduce Side Effects in Modern Drug Development
Oxford Professor Of Chemistry And Founder Of Therapeutic Company Wins Two International Awards
Meet Peter McNamara, Ph.D., Tectonic’s SVP, Head of Research
Sosei Heptares Announces Antitrust Clearance of License Agreement with Neurocrine Biosciences
Addex Raises $10 Million In Equity Financing
Trevena Announces Advancement of TRV045 Into Clinical Development for Diabetic Neuropathic Pain
Perkins’ Head of Molecular Endocrinology and Pharmacology, Professor Kevin Pfleger, was appointed...
VIB spin-off Confo Therapeutics Enters Collaborative Agreement with Regeneron
Crinetics Pharmaceuticals announced the formation of an independently operated new company...
Orion Announces The Rapid Lead Optimization Of Ob-004 - A Ccr2 Antagonist
Neurocrine Biosciences Announces Positive Phase 3 Data for KINECT-HD Study Evaluating Valbenazine...
First in Human: Early-stage COVID therapies hold promise against omicron variant
OMass Therapeutics's founder, Carol Robinson, has been awarded the prestigious Louis-Jeantet ...
Sosei Heptares Enters Antibody Discovery Agreement with Twist Bioscience to Discover and Develop ...
New structural perspectives in G protein-coupled receptor-mediated Src family kinase activation